Personalis And Tempus Expand Collaboration; Tempus Invests $36M By Exercising Warrants To Purchase 9.2M Shares Of Common Stock At An Average Price Of $2 And To Purchase 3.5M Additional Shares At a Price Of $5.07
Portfolio Pulse from Benzinga Newsdesk
Personalis, Inc. (NASDAQ:PSNL) and Tempus AI, Inc. (NASDAQ:TEM) have expanded their collaboration, with Tempus investing $36 million by exercising warrants and purchasing additional shares. The partnership aims to accelerate the commercialization of ultra-sensitive MRD testing for cancer patients.
August 16, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Personalis, Inc. (PSNL) has expanded its collaboration with Tempus, which includes a $36 million investment from Tempus. This investment will help accelerate the commercialization of Personalis' ultra-sensitive MRD testing.
The $36 million investment from Tempus will provide Personalis with the necessary capital to accelerate the commercialization of its MRD testing, likely leading to increased revenue and market presence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Tempus AI, Inc. (TEM) has expanded its collaboration with Personalis, investing $36 million to accelerate the commercialization of ultra-sensitive MRD testing. This move strengthens Tempus' position in the cancer diagnostics market.
By investing $36 million in Personalis, Tempus is solidifying its role as a key player in the cancer diagnostics market, which could lead to increased market share and revenue growth.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80